ticlopidine hydrochloride

Also found in: Dictionary.
Related to ticlopidine hydrochloride: Ticlid

ticlopidine hydrochloride

Apo-Ticlopidine, Dom-Ticlopidine, Gen-Ticlopidine, Novo-Ticlopidine, NU-Ticlopidine, PMS-Ticlopidine, Sandoz Ticlopidine, Ticlid

Pharmacologic class: Platelet aggregation inhibitor

Therapeutic class: Antiplatelet agent

Pregnancy risk category B

FDA Box Warning

Drug may cause life-threatening hematologic adverse reactions, including neutropenia, agranulocytosis, thrombotic thrombocytopenic purpura (TTP), and aplastic anemia. Such reactions may arise within several days of starting therapy. TTP incidence peaks after about 3 to 4 weeks; neutropenia, at approximately 4 to 6 weeks; and aplastic anemia, after about 4 to 8 weeks. Thereafter, incidence of hematologic reactions declines.

During first 3 months of therapy, monitor patient hematologically and clinically for evidence of neutropenia or TTP. If it occurs, discontinue drug immediately.


Inhibits release of first and second phases of adenosine diphosphate-induced effects on platelet aggregation, preventing thrombus formation


Tablets: 250 mg

Indications and dosages

To reduce risk of thrombotic cerebrovascular accident when aspirin is ineffective or intolerable

Adults: 250 mg P.O. b.i.d. with meals

Adjunctive therapy to prevent subacute stent thrombosis in patients with implanted coronary stents

Adults: 250 mg P.O. b.i.d. with meals, given with antiplatelet doses of aspirin for up to 30 days after successful stent implantation

Dosage adjustment

• Renal impairment

Off-label uses

• Chronic arterial occlusion
• Coronary artery bypass graft
• Open-heart surgery
• Intermittent claudication
• Primary glomerulonephritis
• Sickle cell disease
• Subarachnoid hemorrhage
• Uremic patients with atrioventricular shunts or fistulas


• Hypersensitivity to drug
• Hematopoietic disorders
• Hemostatic disorders or active bleeding
• Severe hepatic disease
• History of thrombotic thrombocytopenia purpura (TTP) or aplastic anemia


Use cautiously in:
• renal or hepatic impairment
• high risk for bleeding
• elderly patients
• pregnant or breastfeeding patients
• children younger than age 18 (safety not established).


• Give with meals.
• Don't give within 2 hours of antacids.

Adverse reactions

CNS: dizziness, headache, weakness, intracerebral bleeding

EENT: conjunctival hemorrhage, tinnitus, epistaxis

GI: nausea, vomiting, diarrhea, full sensation, GI pain, dyspepsia, flatulence, anorexia, GI bleeding

GU: hematuria

Hematologic: ecchymosis, eosinophilia, purpura, TTP, thrombocytosis, neutropenia, agranulocytosis, bone marrow depression

Skin: rashes, bruising, pruritus, urticaria

Other: pain, posttraumatic or perioperative bleeding


Drug-drug. Antacids: decreased ticlopidine blood level

Aspirin: potentiation of aspirin's effect on platelets

Cimetidine (long-term use): reduced ticlopidine clearance

Digoxin: slightly decreased digoxin blood level

Phenytoin: increased phenytoin blood level, greater risk of toxicity

Theophylline: decreased theophylline clearance, greater risk of toxicity

Vitamin A: altered anticoagulant effects

Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase: increased levels

Granulocytes, neutrophils, platelets, white blood cells: decreased counts

Liver function tests: abnormal results

Drug-food. Any food: increased ticlopidine absorption

Drug-herbs. Alfalfa, anise, arnica, astragalus, bilberry, black current seed oil, bladderwrack, bogbean, boldo, borage oil, buchu, capsacin, cat's claw, celery, chapparal, cinchona bark, clove oil, coenzyme Q10, dandelion, dong quai, evening primrose oil, fenugreek, feverfew, garlic, ginger, gingko, guggal, papaya extract, red clover, rhubarb, safflower oil, skullcap, St. John's wort, tan shen: altered anticoagulant effects

Patient monitoring

Closely monitor coagulation studies and CBC with white cell differential. Watch for evidence of bleeding tendency and blood dyscrasias.

Assess neurologic status carefully. Stay alert for signs and symptoms of intracranial bleeding.
• Monitor liver function tests.

Patient teaching

• Tell patient to take with meals, but not within 2 hours of antacids.

Instruct patient to immediately report easy bruising or bleeding.
• Advise patient to stop taking drug 10 to 14 days before elective surgery.
• Tell patient to inform all prescribers that he is taking drug.
• Inform patient that aspirin-containing products and many herbs increase risk of bleeding. Urge him to consult prescriber before taking over-the-counter drugs or herbs.
• Caution patient to avoid activities that can cause injury. Tell him to use soft toothbrush and electric razor to avoid gum and skin injury.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, and herbs mentioned above.

References in periodicals archive ?
Ticlopidine hydrochloride was put on sale in Japan in 1981 and about 1 million people are taking it each year.
Vice president of sales Jack Bleau says the ability to be first to market with ticlopidine hydrochloride has given Apotex a high level of credibility.
The immediate-release isosorbide mononitrate tablets are the third FDA approval received by Faulding for the 1998/99 financial year, following the tentative approvals of diltiazem hydrochloride extended-release capsules and ticlopidine hydrochloride tablets.
We have been informed by the FDA that our Abbreviated New Drug Application (ANDA) for ticlopidine hydrochloride tablets, 250 mg, the generic version of Ticlid(R) brand tablets, is approvable in all respects related to the safety and efficacy of the product for use as recommended in the product labeling.
Ticlopidine hydrochloride is a blood thinner indicated to reduce the risk of fatal and non-fatal thrombotic strokes.
The FDA has informed Purepac that the only block to Purepac's receipt of final marketing clearance is the FDA's recent determination that the first company to file an ANDA with respect to ticlopidine hydrochloride is entitled to a 180-day head start in the market commonly known as "market exclusivity" - despite the fact that the first ANDA applicant was not sued for patent infringement by the brand company," Mr Moldin explained.
Purepac's ANDA for ticlopidine hydrochloride appears to be the first that has been blocked by the FDA's new Guidance for Industry that was issued on 22 June 1998.